Document is current
Any future updates will be listed below
-
Authors
Cole, John J.
McColl, Alison
Shaw, Robin
Lynall, Mary-Ellen
Cowen, Philip J. https://orcid.org/0000-0001-5518-6138
de Boer, Peter
Drevets, Wayne C.
Harrison, Neil https://orcid.org/0000-0002-9584-3769
Pariante, Carmine https://orcid.org/0000-0002-9132-5091
Pointon, Linda https://orcid.org/0000-0003-2738-8589
,
Goodyear, Carl
Bullmore, Edward
Cavanagh, Jonathan https://orcid.org/0000-0003-0640-8050
-
Funding
Funding for this research was provided by:
Wellcome Trust (104025, 104025, 104025, 104025, 104025, 104025, 104025, 104025, 104025)
- License Information
-
More Information
Article History
Received: 30 September 2020
Revised: 20 April 2021
Accepted: 10 June 2021
First Online: 22 July 2021
Conflict of interest
: This work was funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium, which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer. Dr. Drevets and Dr. De Boer are employees of Janssen Research & Development, LLC, of Johnson & Johnson and hold equity in Johnson & Johnson.
